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Purpose: To further explore the spectrum of mutations in the Visual System Homeobox 2 (VSX2/CHX10) gene previously
found to be associated with autosomal recessive microphthalmia.
Methods: We screened 95 probands with syndromic or isolated developmental ocular conditions (including 55 with
anophthalmia/microphthalmia) for mutations in VSX2.
Results: Homozygous mutations in VSX2 were identified in two out of five consanguineous families with isolated
microphthalmia. A novel missense mutation, c.668G>C (p.G223A), was identified in a large Pakistani family with multiple
sibships affected with bilateral microphthalmia. This p.G223A mutation affects the conserved CVC motif that was shown
to be important for DNA binding and repression activities of VSX2. The second mutation, c.249delG (p.Leu84SerfsX57),
was identified in an Iranian family with microphthalmia; this mutation has been previously reported and is predicted to
generate a severely truncated mutant protein completely lacking the VSX2 homeodomain, CVC domain and COOH-
terminal regions.
Conclusions: Mutations in VSX2 represent an important cause of autosomal recessive microphthalmia in consanguineous
pedigrees. Identification of a second missense mutation in the CVC motif emphasizes the importance of this region for
normal VSX2 function.
VSX2 (Visual System homeobox 2, formerly known as
CHX10) is a homeodomain containing transcription factor
expressed in the developing retina in human [1], mouse [2],
and zebrafish embryos [3,4]; VSX2/Vsx2 deficiency results in
microphthalmia with various associated ocular anomalies in
all three species [1-3], suggesting that the function of this gene
is  evolutionarily  conserved.  The  VSX2  homeoprotein  is
believed to mostly act as a repressor and, in some contexts, a
weak  activator,  and  utilizes  the  homeodomain  and  CVC
domain in its interaction with DNA [5].
Mutations  in  VSX2  are  associated  with  autosomal
recessive  anophthalmia/microphthalmia  (A/M),  with  or
without iris coloboma and other ocular anomalies; eleven
families  have  been  described  with  eight  different  VSX2
mutations [1,6-9]. In most cases, the ocular anomalies are
isolated,  but  occasional  extraocular  features  have  been
reported,  including  learning  difficulties  and  hormone
deficiency  [9].  All  affected  individuals  have  homozygous
mutations; to date, mutations have only been identified in
consanguineous kindreds, primarily of West and South Asian
background.  Two  previous  studies  failed  to  identify  any
VSX2 mutations in 150 probands with A/M from Scotland
[10] and 50 from Mexico [11].
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A/M is a heterogeneous condition with numerous known
causative  genes.  The  most  common  causes  of  A/M  are
associated with autosomal-dominant inheritance and include
SRY-Box  2  (SOX2)  [12],  Orthodenticle  Homeobox  2
(OTX2) [13], and Bone Morphogenetic Protein 4 (BMP4)
[14]  mutations.  Several  recessive  alleles  have  also  been
reported.  Homozygous  and/or  compound  heterozygous
mutations  have  been  identified:  in  Forkhead  Box  E3
(FOXE3)  in  several  families  affected  with  nonsyndromic
microphthalmia, often accompanied by aphakia and anterior
segment anomalies [15-19]; in Retina and Anterior Neural
Fold  Homeobox  Gene  (RAX)  in  two  probands  with
nonsyndromic anophthalmia [20,21]; and in Stimulated by
Retinoic Acid 6 (STRA6) in syndromic A/M patients [22-24].
To further characterize the spectrum of VSX2 mutations
in A/M and other eye disease, we undertook screening of this
gene  in  a  large  cohort  of  patients  with  various  ocular
conditions.
METHODS
This human study was approved by the Institutional Review
Board of the Children’s Hospital of Milwaukee, WI with
informed  consent  obtained  by  local  physicians  for  every
subject.
Genomic DNA was isolated from whole blood or buccal
samples using standard procedures. The entire coding region
and  exon-intron  junctions  of  VSX2  (reference  sequence
NM_182894.2) were screened by direct DNA sequencing of
PCR products in cases and controls, as previously described
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2527[17] with five sets of primers (Table 1). Briefly, PCR products
were  sequenced  using  3730XL  DNA  Analyzer  (Applied
Biosystems,  Foster  City,  CA)  and  results  were  analyzed
manually  and  using  Mutation  Surveyor  software
(SoftGenetics,  State  Collge,  PA).  All  initially  identified
changes were confirmed by additional independent PCR and
sequencing experiments.
We screened 95 patients with ocular disorders, including
55 with A/M, 17 with anterior segment dysgenesis, 5 with
coloboma, and 18 with other ocular conditions. There were 6
probands with autosomal recessive microphthalmia: all were
consanguineous  kindreds  and  five  demonstrated  multiple
individuals with isolated microphthalmia in a clear recessive
pattern. Race/ethnicity for the patients with anophthalmia/
microphthalmia included Asian (7), African American (2),
Caucasian (34), Hispanic (8), and other (4) and for the patients
with  other  diagnoses  included  Asian  (1),  Caucasian  (32),
Hispanic  (3),  and  other  (4).  Race-specific  Caucasian  and
Asian  control  panels,  as  described  previously  [17],  were
screened for the identified mutations.
RESULTS
Homozygous  mutations  in  VSX2  were  identified  in  two
probands from consanguineous kindreds.
Patient 1 is an 11-year-old Pakistani male with isolated
bilateral  microphthalmia.  He  was  found  to  have  a
homozygous c.668G>C (p.G223A) mutation, not previously
reported.  There  is  an  extensive  family  history  of
consanguinity and microphthalmia; the mutation cosegregates
with  the  disease  phenotype  with  all  affected  individuals
homozygous  for  the  mutation  and  all  tested  unaffected
individuals either heterozygous carriers or wild type (Figure
1).
Patient 2 is a 26-year-old Iranian female with bilateral
microphthalmia, ‘disorganized eye,’ and blindness. She was
found  to  have  a  homozygous  c.249delG  mutation
(p.Leu84SerfsX57), previously reported [9].The parents are
first cousins and there is a history of a similar phenotype in
two  siblings;  the  mutation  cosegregates  with  the  disease
phenotype (Figure 2). An affected brother is homozygous for
the  mutation  while  the  two  unaffected  siblings  and  the
unaffected  parents  are  heterozygous  carriers  and  an
unaffected maternal aunt is wild type. The other two siblings
were not available for testing.
Neither  mutation  was  observed  in  control  samples
including 96 Asians and 94 Caucasian individuals. The first
mutation is predicted to change a highly conserved amino acid
inside the CVC-motif while the second mutation is predicted
to result in a severely truncated mutant protein lacking the
homeodomain,  CVC-motif,  COOH-terminal  region,  and  a
portion of the NH2-terminal arm (Figure 3).
DISCUSSION
These data confirm the role of VSX2 in autosomal recessive
isolated  microphthalmia.  Similar  to  previous  reports,
mutations were identified in consanguineous kindreds from
Pakistan and Iran and no causative mutations were seen in
probands  with  A/M  from  non-consanguineous  kindreds.
VSX2  mutations  were  identified  in  33%  (2  out  of  6)  of
consanguineous families with isolated microphthalmia.
The novel missense mutation seen in Patient 1, c.668G>C
(p.Gly223Ala), is located within the conserved CVC motif,
similar to the previously reported p.Arg227Trp mutation [6,
9]. The absence of this mutation in controls and its perfect
cosegregation  with  disease  phenotype  provides  strong
evidence that this change disrupts VSX2 function. The CVC
motif is shared between the members of human VSX family,
VSX1 and VSX2, as well as their numerous orthologs in other
species. The glycine at position 16 of the CVC motif altered
by this mutation is conserved in all known VSX proteins
including  the  C.  elegans  protein  ceh-10  [13].  The  VSX2
homeodomain  and  CVC  motif  were  demonstrated  to  be
sufficient for DNA binding and repression; a deletion of the
CVC motif resulted in a mild alteration of DNA binding but
severely affected its repression ability [5].
This  is  the  second  report  of  the  c.249delG  mutation,
previously  reported  in  two  sisters  from  Iran  with
microphthalmia, coloboma, and no perception of light [9].
Electroretinography (ERG) was performed on both parents in
the previous report and demonstrated inner retinal dysfunction
in  both,  suggesting  a  possible  dominant  effect  for  this
mutation [9]. Unfortunately, we were unable to obtain ERG
data for the heterozygous relatives of Patient 2 and thus cannot
determine whether any mild retinal dystrophy is present in this
family.
TABLE 1. PRIMER SEQUENCES AND CONDITIONS FOR AMPLIFICATION OF VSX2 EXONS.
Set/exon Forward primer sequence Reverse primer sequence PCR
product
Annealing temp/ special
conditions
Set 1/exon 1 TCCAGAGCATTAGACACCGG TGGCAGGAACTTTTCCGCCT 603 bp 55 °C (5% DMSO; 20%
Betaine)
Set 2/exon 2 GTTCAAAACCTCCGGATTCG TCCGTTGTCGGCGAAAATAG 392 bp 55 °C
Set 3/exon 3 TCTTGTCTGAGACAGGCTCT TCATGGGCATCTGGAACCCT 268 bp 55 °C (5% DMSO; 20%
Betaine)
Set 4/exon 4 CACCATGGAGTAGGCGAGCT ATTTCTCTCCTGCTAGGCTG 432 bp 55 °C
Set 5/exon 5 CAGTTCAAGATGGCTTTCCC ATGTCTCAGCATGGTCCAGA 574 bp 55 °C
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are consistent with the previously described VSX2 spectrum.
The absence of mutations in syndromic A/M cases is also in
agreement with previous studies and further supports an eye-
specific role for this gene in humans. This is only the second
report of a missense mutation predicted to affect the VSX2
CVC motif and resulting in a microphthalmia phenotype. The
identification of this mutation emphasizes the importance of
Figure 1. Pedigree and VSX2 sequencing results for Patient 1 and family members. A: Patient 1 is indicated with a black arrow. VSX2 genotype
is indicated for each family member tested; genotypes of affected individuals are shown in red. WT, wild type. B: Mutation Surveyor view
of forward VSX2 sequencing data are shown; the position of the mutation is indicated with an arrow.
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2529Figure 2. Pedigree and VSX2 sequencing results for Patient 2 and family members. A: Patient 2 is indicated with a black arrow. VSX2 genotype
is indicated for each family member tested; genotypes of affected individuals are shown in red. WT, wild type; NT, not tested. B: Mutation
Surveyor view of reverse VSX2 sequencing data are shown; the position of the mutation is indicated with an arrow; the first position displaying
the “phase shift” in the electropherogram trace which is characteristic of a heterozygous deletion is indicated with an asterisk.
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2530the  CVC  motif  for  normal  VSX2  function  and  provides
opportunities for further functional dissection.
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